Xenon Pharmaceuticals Q3 Earnings Call Highlights

Xenon Pharmaceuticals (XENE) reported Q3 2026 results, with R&D expenses at $95.6M and net loss of $110.4M. The company submitted an NDA for azetukalner in focal seizures and expects X-NOVA2 study results in December 2026. Xenon plans Phase 2 studies for XEN1701 and XEN1120 in acute pain in 2027.

Xenon Pharmaceuticals (XENE) reported Q3 2026 progress, including FDA NDA submission for AZK, its epilepsy drug candidate. AZK showed significant efficacy in reducing seizure frequency and a strong safety profile. The company also announced plans for a Phase IIIb/IV study (X-FIRST) and progress in its psychiatry and pain programs, including XEN1701 and XEN1120. Enrollment in the Phase III X-NOVA2 study for MDD was completed, with data expected in December 2026.

Xenon Pharmaceuticals (XENE) reported $1.2B in cash reserves, funding operations into 2029. CEO Ian Mortimer discussed azetukalner's (AZK) potential in epilepsy and psychiatry, noting X-NOVA2 data due in December 2026. XEN1701's development was addressed, with the company confident in its design and safety profile. X-FIRST study plans were outlined, targeting earlier-line patients and general neurologists. Dose selection and FDA feedback were also discussed.

Xenon Pharmaceuticals (XENE) stock fell 2.4% in after-hours trading to $39.50 after reporting Q3 2026 results. The company posted a net loss of $110.4M, beating estimates but widening from the prior year. Revenue missed forecasts. R&D expenses rose due to late-stage programs. The stock was pressured by a voluntary pause in depression trials. The company submitted a New Drug Application for azetukalner and reported a $1.15B cash position.

Xenon Pharmaceuticals Inc. (XENE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xenon Reports Q3 2026 Financial Results and Provides Business Update • New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 • Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3

Xenon Pharmaceuticals reported positive Phase 1 results for XEN1701 and XEN1120, supporting their advancement to Phase 2 studies in acute pain. XEN1701 achieved target NaV1.7 receptor occupancy and was well-tolerated. XEN1120 demonstrated plasma levels predictive of analgesic effects. Phase 2 studies are expected to begin in H1 2027. According to the company, preclinical data showed significant pain reduction in non-human primates.